NASDAQ$ETNB
89Bio Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
89bio reported first quarter 2023 financial results and provided a corporate update.
89bio reported positive topline results from the ENLIVEN Phase 2b trial of pegozafermin in NASH, demonstrating high statistical significance on both primary histology endpoints. The company completed an underwritten public offering with $316.2 million in gross proceeds and had a cash balance of $480.9 million as of March 31, 2023.
- Positive topline results from ENLIVEN Phase 2b trial of pegozafermin in NASH demonstrated high statistical significance on both primary histology endpoints supporting advancement to Phase 3.
- Discussions with regulatory agencies are planned for the second half of 2023.
- SHTG Phase 3 trial is expected to be initiated in the second quarter of 2023.
- Completed underwritten public offering with $316.2 million in gross proceeds; cash balance of $480.9 million as of March 31, 2023.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Forward guidance
89bio is focused on advancing pegozafermin through clinical development for NASH and SHTG. The company plans to meet with the FDA and pursue EU scientific advice. Clinical development plans include Phase 3 trials for F2/F3 and F4 patients.
Tailwinds
- Pegozafermin shows therapeutic potential and clinical benefits.
- Pegozafermin has a favorable safety and tolerability profile.
- Phase 3 trial in SHTG is expected to be initiated.
- Phase 3 trial is planned based on results from the Phase 2b ENLIVEN trial.
- The company expects to meet with regulatory authorities.
Headwinds
- Positive results from clinical studies may not be predictive of future results.
- 89bio is substantially dependent on the success of its lead product candidate.
- Competition from competing products.
- Impact of general economic, health, industrial, or political conditions.
- Sufficiency of 89bio’s capital resources and ability to raise additional capital.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro